{
    "clinical_study": {
        "@rank": "112683", 
        "arm_group": [
            {
                "arm_group_label": "MHAA4549A", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Tamiflu", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized, double-blind, placebo-controlled study will evaluate the efficacy and\n      safety of MHAA4549A in healthy volunteers in an influenza challenge model. Subjects will be\n      intranasally oculated with the challenge virus and will be randomly assigned to receive a\n      intravenous dose of either MHAA4549A or placebo. In the stage 5 cohort, subjects will be\n      randomly assigned to receive doses of MHAA4549A or placebo or Tamiflu (oseltamivir) orally\n      twice daily for 5 days. All subjects in all cohorts may take Tamiflu twice daily from Day 7\n      to Day 11."
        }, 
        "brief_title": "A Study of MHAA4549A in Healthy Volunteers in an Influenza Challenge Model", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteer", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  In good health with no history of major medical conditions from medical history,\n             physical examination and routine laboratory tests\n\n          -  Male subjects and women of child-bearing potential must use effective contraception\n             as defined by protocol, starting at entry to quarantine and continuing until Day 120\n             follow-up visit\n\n          -  Sero-suitable for challenge virus\n\n        Exclusion Criteria:\n\n          -  Women who have been pregnant within 6 months prior to the study, or who have been\n             breastfeeding within 3 months prior to the study, or who have a positive pregnancy\n             test at any point in the study\n\n          -  Any history or evidence of any clinically significant cardiovascular,\n             gastrointestinal, endocrinological, haematological, hepatic, immunological,\n             metabolic, urological, neurological, psychiatric, renal, and/or other major disease\n             or malignancy, as judged by the CI\n\n          -  Abnormal pulmonary function evidenced by clinically significant abnormalities in\n             spirometry\n\n          -  History of asthma, COPD, pulmonary hypertension, reactive airway disease, or chronic\n             lung disease of any etiology. A history of childhood asthma before the age of 12 is\n             acceptable provided the subject is asymptomatic without treatment.\n\n          -  History suggestive of respiratory infection within 14 days prior to admission to the\n             unit"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "101", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01980966", 
            "org_study_id": "GV28985", 
            "secondary_id": "2013-001983-52"
        }, 
        "intervention": [
            {
                "arm_group_label": "MHAA4549A", 
                "description": "IV dose", 
                "intervention_name": "MHAA549A", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "IV dose", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Tamiflu", 
                "description": "Orally b.i.d, 5 days", 
                "intervention_name": "oseltamivir [Tamiflu]", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Oseltamivir"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 12, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "NW1 0NH"
                }
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study in Healthy Volunteers to Evaluate the Efficacy and Safety of MHAA4549A in an Influenza Challenge Model", 
        "overall_official": {
            "affiliation": "Genentech", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Viral area under the concentration-time curve (AUC) of nasopharyngeal viral load by quantitative Polymerase Chain Reaction (qPCR)", 
            "safety_issue": "No", 
            "time_frame": "8 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01980966"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "120 days"
            }, 
            {
                "measure": "Safety: Change in lung function", 
                "safety_issue": "No", 
                "time_frame": "from pre-challenge to Day 29"
            }, 
            {
                "measure": "Safety: Incidence of anti-therapeutic antibodies (ATAs)", 
                "safety_issue": "No", 
                "time_frame": "120 days"
            }, 
            {
                "measure": "Pharmacokinetics: Area under the concentration-time curve", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "measure": "AUC of nasopharyngeal viral load, as measured by cell culture", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "measure": "Peak viral load (qPCR and cell culture)", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "measure": "Duration of viral shedding", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "measure": "Duration of Grade 2 or worse symptoms (from first occurrence of any Grade >2 symptom to last occurrence of any Grade >2 symptom)", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "measure": "Peak/AUC of composite symptoms", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }
        ], 
        "source": "Genentech", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}